Matthew Henn, Ph.D.

Matthew Henn, Ph.D.

President and Chief Scientific OfficeratSeres Therapeutics· In the 2025 proxy

Pay in FY2025Seres Therapeutics stock -10.5% the same year

Matthew Henn, Ph.D. was paid $1.0M in FY2025 (Dec). Seres Therapeutics stock fell 10.5% that year.

Pay$100 in the stock at the end of FY24 → $90
Pay is from the Summary Compensation Table of each Seres Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Seres TherapeuticsPublic company · 1 yr
    • President and Chief Scientific Officer2025 – Present · 1 yrStock in role -91%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?